Skip Navigation

Products developed with Acura's proprietary Aversion® Technology are intended to deter or discourage common methods of prescription drug abuse:

  • Intentionally swallowing excess quantities of tablets
  • Crushing and nasally snorting tablets
  • Injecting dissolved tablets with a syringe

dr.home

Lead Candidate

Acurox® (oxycodone HCl/niacin) is an immediate release tablet product for pain relief utilizing Aversion® Technology. Acura and King met with the U.S. Food and Drug Administration (FDA) on September 2, 2009 to discuss the issues raised in the FDA’s June 30, 2009 Complete Response Letter (”CRL”) and have agreed to take the NDA to an FDA Advisory Committee.



Collaboration

Acura has entered into a license agreement with King Pharmaceuticals, Inc. to develop and commercialize opioid analgesic products utilizing our proprietary Aversion® Technology, including Acurox® Tablets.


Innovation

Acura’s strategy includes continued investment in novel solutions to prescription drug abuse. We have three issued U.S. patents covering our Aversion® Technology with numerous US and international patent applications pending.